Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substances Generally Recognized as Safe: Notification Procedure, 29216-29217 [2019-13220]

Download as PDF 29216 Federal Register / Vol. 84, No. 120 / Friday, June 21, 2019 / Notices TABLE 3—STUDY 2 DESIGN: HEMATOLOGY Indication presentation Material information in superimposed text only Material information in audio only Material information in superimposed text + audio Material information not in superimposed text or audio (Control) Audio: Drug Y is used to treat multiple myeloma. Superimposed text: Drug Y is used to treat multiple myeloma in combination with dexamethasone, in people who have received at least three prior medicines to treat multiple myeloma. Audio: Drug Y is used to treat multiple myeloma in combination with dexamethasone, in people who have received at least three prior medicines to treat multiple myeloma. Superimposed text: Drug Y is used to treat multiple myeloma. Audio: Drug Y is used to treat multiple myeloma in combination with dexamethasone, in people who have received at least three prior medicines to treat multiple myeloma. Superimposed text: Drug Y is used to treat multiple myeloma in combination with dexamethasone, in people who have received at least three prior medicines to treat multiple myeloma. Audio: Drug Y is used to treat multiple myeloma. Superimposed text: Drug Y is used to treat multiple myeloma. Note. Study 2 will use the overall survival ad from Study 1. FDA estimates the burden of this collection of information as follows: TABLE 4—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents Activity Total annual responses Average burden per response Total hours Cognitive Interview screener ................................ Cognitive Interviews .............................................. Pretests 1 and 2 screener .................................... Pretests 1 and 2 ................................................... Study 1 screener .................................................. Study 1 .................................................................. Study 2 screener .................................................. Study 2 .................................................................. 30 18 200 120 1,167 700 867 520 1 1 1 1 1 1 1 1 30 18 200 120 1,167 700 867 520 0.08 (5 minutes) ........... 1 (60 minutes) .............. 0.08 (5 minutes) ........... 0.33 (20 minutes) ......... 0.08 (5 minutes) ........... 0.33 (20 minutes) ......... 0.08 (5 minutes) ........... 0.33 (20 minutes) ......... 2.4 18 16 39.6 93.36 231 69.36 171.6 Total ............................................................... ........................ ........................ ........................ ....................................... 641.32 1 There are no capital costs or operating and maintenance costs associated with this collection of information. II. References The following references are on display with the Dockets Management Staff (see ADDRESSES) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; these are not available electronically at https:// www.regulations.gov as these references are copyright protected. Some may be available at the website address, if listed. FDA has verified the website addresses, as of the date this document publishes in the Federal Register, but websites are subject to change over time. jspears on DSK30JT082PROD with NOTICES Number of responses per respondent for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements.’’ Journal of Public Policy & Marketing, 35(1):108–123, 2016. 3. Sullivan, H.W., V. Boudewyns, A.C. O’Donoghue, et al., ‘‘Attention to and Distraction from Risk Information in Prescription Drug Advertising: An EyeTracking Study.’’ Journal of Public Policy & Marketing, 36(2):236–245, 2017. Dated: June 14, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. 18:30 Jun 20, 2019 Jkt 247001 Food and Drug Administration [Docket No. FDA–2012–N–0021] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substances Generally Recognized as Safe: Notification Procedure AGENCY: [FR Doc. 2019–13128 Filed 6–20–19; 8:45 am] HHS. BILLING CODE 4164–01–P ACTION: 1. Kim, J., J. Gao, L. Amiri-Kordestani, et al., ‘‘Patient-Friendly Language to Facilitate Treatment Choice for Patients with Cancer.’’ The Oncologist, 10.1634/ theoncologist.2018-0761, 2019. Available from: https:// theoncologist.alphamedpress.org/ content/early/2019/05/16/ theoncologist.2018-0761.short?rss=1. 2. Aikin, K.J., A.C. O’Donoghue, C.M. Squire, et al., ‘‘An Empirical Examination of the FDAAA-Mandated Toll-Free Statement VerDate Sep<11>2014 DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Food and Drug Administration, Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by July 22, 2019. SUMMARY: Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\21JNN1.SGM 21JNN1 29217 Federal Register / Vol. 84, No. 120 / Friday, June 21, 2019 / Notices To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202– 395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0342. Also include the FDA docket number found in brackets in the heading of this document. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–5733, PRAStaff@ fda.hhs.gov. In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. SUPPLEMENTARY INFORMATION: Substances Generally Recognized as Safe (GRAS): Notification Procedure— 21 CFR Part 170, Subpart E and 21 CFR Part 570, Subpart E OMB Control Number 0910–0342— Extension The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that all food additives (as defined by section 201(s) (21 U.S.C. 321(s)) be approved by FDA before they are marketed. Section 409 of the FD&C Act (21 U.S.C. 349) establishes a premarket approval requirement for ‘‘food additives.’’ Section 201(s) of the FD&C Act provides an exclusion to the definition of food additive and thus from the premarket approval requirement, for uses of substances that are GRAS by qualified experts. The GRAS provision of section 201(s) of the FD&C Act is implemented in (part 170) 21 CFR part 170 and (part 570) 21 CFR part 570 for human food and animal food, respectively. Part 170, subpart E and part 570, subpart E provide a standard format for the submission of a notice. This collection utilizes a voluntary administrative procedure for notifying FDA about a conclusion that a substance is GRAS under the conditions of its intended use in human food or animal food. The information submitted to us in a GRAS notice is necessary to allow us to administer efficiently the FD&C Act’s various provisions that apply to the use of substances added to food, specifically with regard to whether a substance is GRAS under the conditions of its intended use or is a food additive subject to premarket review. We use the information collected through the GRAS notification procedures to complete our evaluation within specific timelines. Description of Respondents: The respondents to this collection of information are manufacturers of substances used in human food and animal food and feed. In the Federal Register of March 12, 2019 (84 FR 8876), we published a 60day notice requesting public comment on the proposed collection of information. No comments were received. We estimate the burden of the information collection as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents Activity; 21 CFR section GRAS notification procedure for human food; 170.210– 170.280 (part 170, subpart E) .......................................... GRAS notification procedure for animal food and animal feed; 570.210–570.280 (part 570, subpart E) .................. Total .............................................................................. 1 There Number of responses per respondent Average burden per response Total hours 100 1 100 170 17,000 25 1 25 170 4,250 ........................ ........................ 75 ........................ 21,250 are no capital costs or operating and maintenance costs associated with this collection of information. Our estimated burden reflects an overall increase of 8,500 hours, which corresponds to an increase in GRAS submissions for human food from 50 to 100 we have received over the last 2 years. Dated: June 17, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–13220 Filed 6–20–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Health Resources and Services Administration (HRSA), Department of Health and Human Services. ACTION: Notice. FOR FURTHER INFORMATION CONTACT: In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget 18:30 Jun 20, 2019 Jkt 247001 Comments on this Information Collection Request must be received no later than August 20, 2019. DATES: ADDRESSES: SUMMARY: VerDate Sep<11>2014 (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR. Agency Information Collection Activities: Proposed Collection: Public Comment Request Information Collection Request Title: Small Rural Hospital Transition Project (SRHT), OMB No. 0906–0026—Extension AGENCY: jspears on DSK30JT082PROD with NOTICES Total annual responses PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 Submit your comments to paperwork@hrsa.gov or mail the HRSA Information Collection Clearance Officer, Room 14N136B, 5600 Fishers Lane, Rockville, Maryland 20857. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email paperwork@hrsa.gov or call Lisa Wright-Solomon, the HRSA Information Collection Clearance Officer at (301) 443–1984. When submitting comments or requesting information, please include the SUPPLEMENTARY INFORMATION: E:\FR\FM\21JNN1.SGM 21JNN1

Agencies

[Federal Register Volume 84, Number 120 (Friday, June 21, 2019)]
[Notices]
[Pages 29216-29217]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-13220]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0021]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Substances Generally 
Recognized as Safe: Notification Procedure

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by July 
22, 2019.

[[Page 29217]]


ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
Fax: 202-395-7285, or emailed to [email protected]. All 
comments should be identified with the OMB control number 0910-0342. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, 
Food and Drug Administration, Three White Flint North, 10A-12M, 11601 
Landsdown St., North Bethesda, MD 20852, 301-796-5733, 
[email protected].

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Substances Generally Recognized as Safe (GRAS): Notification 
Procedure--21 CFR Part 170, Subpart E and 21 CFR Part 570, Subpart E

OMB Control Number 0910-0342--Extension

    The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that 
all food additives (as defined by section 201(s) (21 U.S.C. 321(s)) be 
approved by FDA before they are marketed. Section 409 of the FD&C Act 
(21 U.S.C. 349) establishes a premarket approval requirement for ``food 
additives.'' Section 201(s) of the FD&C Act provides an exclusion to 
the definition of food additive and thus from the premarket approval 
requirement, for uses of substances that are GRAS by qualified experts. 
The GRAS provision of section 201(s) of the FD&C Act is implemented in 
(part 170) 21 CFR part 170 and (part 570) 21 CFR part 570 for human 
food and animal food, respectively. Part 170, subpart E and part 570, 
subpart E provide a standard format for the submission of a notice. 
This collection utilizes a voluntary administrative procedure for 
notifying FDA about a conclusion that a substance is GRAS under the 
conditions of its intended use in human food or animal food. The 
information submitted to us in a GRAS notice is necessary to allow us 
to administer efficiently the FD&C Act's various provisions that apply 
to the use of substances added to food, specifically with regard to 
whether a substance is GRAS under the conditions of its intended use or 
is a food additive subject to premarket review. We use the information 
collected through the GRAS notification procedures to complete our 
evaluation within specific timelines.
    Description of Respondents: The respondents to this collection of 
information are manufacturers of substances used in human food and 
animal food and feed.
    In the Federal Register of March 12, 2019 (84 FR 8876), we 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received. We estimate the 
burden of the information collection as follows:

                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of
    Activity; 21 CFR section         Number of     responses per   Total annual   Average burden    Total hours
                                    respondents     respondent       responses     per response
----------------------------------------------------------------------------------------------------------------
GRAS notification procedure for              100               1             100             170          17,000
 human food; 170.210-170.280
 (part 170, subpart E)..........
GRAS notification procedure for               25               1              25             170           4,250
 animal food and animal feed;
 570.210-570.280 (part 570,
 subpart E).....................
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............              75  ..............          21,250
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Our estimated burden reflects an overall increase of 8,500 hours, 
which corresponds to an increase in GRAS submissions for human food 
from 50 to 100 we have received over the last 2 years.

    Dated: June 17, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-13220 Filed 6-20-19; 8:45 am]
 BILLING CODE 4164-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.